

14.11.2024. THURSDAY HALL A		
08:00-09:15	Special panel Cancer prevention and screening in Serbia – how can we do better? Moderators: Ivan Marković, Ana Jovičević	
08:00-08:15	European Cancer Organization (ECO) screening activities and strategy for the future	Wim Ceelen, ECO
08:15-08:25	Cancer epidemiology in Serbia	Ana Jovičević (IORS)
08:25-09:15	Panel discussion: Ferenc Vicko (Ministry of Health), Verica Jovanović (Institute of Public Health "Dr Milan Jovanovic Batut"), Simona Borštnar (Slovenia), Tanja Španić (Europa Donna Slovenia)	
09:15-09:30	Coffee break	
09:30-10:30	Scientific session 1 Systemic treatment of breast cancer: novelties and dilemmas – part 1: HER2-positive breast cancer Moderators: Ljiljana Stamatović, Natalija Dedić Plavetić	
09:30-09:50	HER2+ breast cancer systemic treatment	Javier Cortes
09:50-10:30	Panel discussion: Joseph Gligorov, Javier Cortes, Otto Metzger	
10:30-10:45	Coffee break	
10:45-11:50	Scientific session 2 Systemic treatment of breast cancer: novelties and dilemmas – part 2: HR-positive/HER2-negative breast cancer Moderators: Simona Borštnar, Snežana Šušnjar	
10:45-11:05	Adjuvant chemotherapy for ER+ breast cancer: advances and a critical overview of therapy de-escalation	Otto Metzger
11:05-11:50	Panel discussion: Joseph Gligorov, Javier Cortes, Otto Metzger	
11:50-12:10	Coffee break	
12:10-13:10	Scientific session 3 Systemic treatment of breast cancer: novelties and dilemmas – part 3: Triple negative breast cancer Moderators: Ivana Božović Spasojević, Lazar Popović	
12:10-12:30	Triple negative breast cancer systemic treatment	Ivana Božović Spasojević
12:30-13:10	Panel discussion: Joseph Gligorov, Javier Cortes, Otto Metzger	
13:10-14:10	Sponsored symposium 1 ROCHE Stepping Into The Spotlight: The Goal Is Cure. Revolution and Evolution of Therapy for Patients with HER2+ Breast Cancer (video material) Welcome and Introduction- Ivana Božović Spasojević Sharing HEReNA story- Ivana Božović Spasojević, Marijana Milović Kovačević, Lazar Popović Raising the bar for HER - PHERGain trial - Javier Cortes Panel discussion: Rewriting HER story - All participants Closing remarks - Ivana Božović Spasojević	

14:10-15:10	Lunch
15:10-15:40	Sponsored symposium 2 ASTRAZENECA Change is coming: Enhertu will write HER Destiny Moderator: Ivana Božović Spasojević Panelists: Lazar Popović, Natalija Dedić Plavetić, Simona Borštnar
15:40-16:25	Sponsored symposium 3 NOVARTIS Evolution of HR+/HER2-breast cancer clinical practice Moderator: Lazar Popović Speakers: Marijana Milović Kovačević, Ana Cvetanović
16:30-16:45	Coffee break
16:45-18:15	Sponsored symposium 4 ELI LILLY Expert Discussion on the CDK4/6i Choices in MBC & EBC Opening words from moderator - Lazar Popović Conducting Risk Assessment to Identify Patients with High-Risk HR+, HER2-EBC. Evolving Standards and Current Guidance - Marijana Milović Kovačević TREATMENT PARADIGM FOR HR+HER2- BREAST CANCER - Joseph Gligorov Managing Adverse Events and Improving Adherence/Persistence in High-Risk HR+, HER2- EBC - Snežana Šušnjar Analyzing the Latest Evidence on CDK4/6 Inhibitors in HR+, HER2- MB - Lazar Popović Panel discussion - all
18:15-19:00	Sponsored symposium 5 PFIZER Are we (RWE) ready? Discussion among experts Moderator: Lazar Popović Speakers: Lazar Popović, Sonja Martinović Šalinger, Ivana Božović, Ana Cvetanović
14.11.2024. THURSDAY HALL B	
08:00-08:30	Sponsored symposium 1 Johnson & Johnson How to achieve better treatment outcomes for patients with EGFR exon20ins mNSCLC? Why do we need novel therapies in EGFR exon20ins NSCLC? - Davorin Radosavljević Clinical study PAPILLON and CHRYSALIS – efficacy data - Bojan Zarić EGFR & MET dual inhibition – safety profile of bispecific antibody - Milica Kontić-Jovanović Panel discussion Davorin Radosavljević, Bojan Zarić, Milica Kontić-Jovanović
08:30-13:30	Lung Cancer Masterclass Organizers: Davorin Radosavljević, Bojan Zarić, Jelena Spasić

08:30-09:15	Lung Cancer Masterclass – part 1 Screening and early detection Moderators: Marko Jakopović, Goran Stojanović	
08:30-08:45	Intro: Why should Lung Cancer screening be implemented?	Vladimir Stojšić
08:45-08:55	Hot topic: Real world data - Croatian experience	Marko Jakopović
08:55-09:15	Panel discussion: Rafal Dziadziuszko, Marko Jakopović, Davorin Radosavljević, Goran Stojanović, Bojan Zarić	
09:15-10:30	Lung Cancer Masterclass – part 2 Advances in early stage non oncogene-addicted NSCLC Moderators: Davorin Radosavljević, Marko Jakopović	
09:15-09:25	Intro: Moving therapy into early stage	Feđa Đorđević
09:25-09:40	New end-points in early-stage clinical trials	Jelena Spasić
09:40-10:00	Decision-making process in early stage non-oncogene addicted NSCLC: neoadjuvant vs. adjuvant vs. perioperative?	Sanjay Popat
10:00-10:15	Stage III beyond PACIFIC	Bojan Zarić
10:15-10:30	Panel discussion: Sanjay Popat, Bojan Zarić, Igor Gómez-Randulfe Rodríguez, Jelena Spasić, Rafal Dziadziuszko	
10:30-10:45	Coffee break	
10:45-12:15	Lung Cancer Masterclass – part 3 Oncogene-addicted NSCLC Moderators: Jelena Spasić, Katja Mohorčić	
10:45-10:55	Intro: Standard of care of EGFR and ALK positive NSCLC	Marko Jakopović
10:55-11:10	New treatment options for advanced EGFR mutated NSCLC	Urška Janžić
11:10-11:25	Advances in other/rare mutations (beyond EGFR and ALK)	Igor Gómez-Randulfe Rodríguez
11:25-11:40	Therapy sequencing and acquired resistance	Sanjay Popat
11:40-11:55	Adjuvant treatment of EGFR and ALK positive NSCLC	Davorin Radosavljević
11:55-12:15	Panel discussion: Davorin Radosavljevic, Sanjay Popat, Marko Jakopović, Urška Janžić, Igor Gómez-Randulfe Rodríguez	
12:15-12:30	Coffee break	
12:30-13:30	Lung Cancer Masterclass – part 4 SCLC Moderators: Bojan Zarić, Urška Janžić	
12:30-12:40	Intro: An area of unmet need or are we doing better in the treatment of SCLC?	Jelena Spasić
12:40-12:55	Radiotherapy in SCLC	Rafal Dziadziuszko
12:55-13:10	Advances in systemic therapy of SCLC	Katja Mohorčić
13:10-13:30	Panel discussion: Jelena Spasić, Rafal Dziadziuszko, Katja Mohorčić, Igor Gómez-Randulfe Rodríguez	

13:30-14:15	Sponsored symposium 2 ROCHE New scenario Moderator: Bojan Zarić Futurospecation - Bojan Zarić New roles - Bojan Zarić, Natalija Samardžić, Davorin Radosavljević Plot twist: Patient on the scene - Bojan Zarić, Natalija Samardžić, Davorin Radosavljević	
14:15-15:10	Lunch	
15:10-15:40	Sponsored symposium 3 ASTRAZENECA EGFRevolution - 20Y of EGFm <i>Expert perspectives and panel discussion</i> Moderator: Bojan Zarić Panelists: Milica Kontić Jovanović, Radmila Janković, Nebojša Marić	
15:40-16:25	Sponsored symposium 4 PFIZER Moderator: Bojan Zarić 1L lorlatinib in ALK+ NSCLC: 5 years later - Marko Jakopović Changing the conversation in 1L ALK+ NSCLC: Treatment decision-making - Bojan Zarić Our experience with Lorlatinib - Natalija Samardžić	
16:25-16:30	Break	
16:30-19:00	ESSO Young Surgeons and Alumni Club (EYSAC) Research Academy Workshop, joined with Serbian Society of Surgical Oncology Organizers: Nada Santrač (EYSAC Chair), Wim Ceelen (EYSAC Research Academy senior lead)	
16:30-16:45	ESSO & EYSAC: where are we now?	Nada Santrač
16:45-17:00	Disparities in cancer treatment	Johnn Henry Herrera Kok
17:00-17:45	Workshop part 1 Moderators: Nada Santrač, Nikolaos Vassos	
17:00-17:30	How to start with translational and clinical research?	Wim Ceelen
17:30-17:45	Q&A	
17:45-18:10	Coffee break	
18:10-18:55	Workshop part 2 Moderators: Wim Ceelen, Milan Kocić	
18:10-18:40	How to best use the RedCap platform for data acquisition and analysis?	Dara Lundon
18:40-18:55	Q&A	
18:55-19:00	Workshop take-home messages Wim Ceelen, Nada Santrač	